uTREAT® (177Lu-CUR-N86)

About Curasight

Curasight is a clinical-stage biotech company with a mission to improve cancer care through a first-in-class theranostics platform targeting the urokinase-type plasminogen activator receptor (uPAR), a key driver of tumor aggressiveness. Its core achievement is the clinical validation of its uTRACE® diagnostic across ~450 patients in eight solid tumor types, which de-risks the parallel development of its therapeutic counterpart, uTREAT®. The company's strategy is to leverage this 'pipeline-in-a-drug' platform across multiple aggressive cancers, initially focusing on brain and prostate cancer, while seeking partners for later-stage development and commercialization.

Therapeutic Areas